Panagopoulos, VN; Bailey, A; Kostopoulos, GK; Ioannides, AA
(2024)
Changes in distinct brain systems identified with fMRI during smoking cessation treatment with varenicline: a review.
Psychopharmacology (Berl), 241 (4).
pp. 653-685.
ISSN 1432-2072
https://doi.org/10.1007/s00213-024-06556-2
SGUL Authors: Bailey, Alexis
|
PDF
Published Version
Available under License Creative Commons Attribution. Download (1MB) | Preview |
Abstract
BACKGROUND: Varenicline is considered one of the most effective treatment options for smoking cessation. Nonetheless, it is only modestly effective. A deeper comprehension of the effects of varenicline by means of the in-depth review of relevant fMRI studies may assist in paving the development of more targeted and effective treatments. METHODOLOGY: A search of PubMed and Google Scholar databases was conducted with the keywords "functional magnetic resonance imaging" or "fMRI", and "varenicline". All peer-reviewed articles regarding the assessment of smokers with fMRI while undergoing treatment with varenicline and meeting the predefined criteria were included. RESULTS: Several studies utilizing different methodologies and targeting different aspects of brain function were identified. During nicotine withdrawal, decreased mesocorticolimbic activity and increased amygdala activity, as well as elevated amygdala-insula and insula-default-mode-network functional connectivity are alleviated by varenicline under specific testing conditions. However, other nicotine withdrawal-induced changes, including the decreased reward responsivity of the ventral striatum, the bilateral dorsal striatum and the anterior cingulate cortex are not influenced by varenicline suggesting a task-dependent divergence in neurocircuitry activation. Under satiety, varenicline treatment is associated with diminished cue-induced activation of the ventral striatum and medial orbitofrontal cortex concomitant with reduced cravings; during the resting state, varenicline induces activation of the lateral orbitofrontal cortex and suppression of the right amygdala. CONCLUSIONS: The current review provides important clues with regard to the neurobiological mechanism of action of varenicline and highlights promising research opportunities regarding the development of more selective and effective treatments and predictive biomarkers for treatment efficacy.
Item Type: | Article | ||||||||
---|---|---|---|---|---|---|---|---|---|
Additional Information: | © The Author(s) 2024 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. | ||||||||
Keywords: | Functional MRI, Nicotine use disorder, Smoking, Smoking cessation, Varenicline, fMRI, Humans, Varenicline, Smoking Cessation, Nicotine, Magnetic Resonance Imaging, Nicotinic Agonists, Brain, Substance Withdrawal Syndrome, Brain, Humans, Substance Withdrawal Syndrome, Nicotine, Nicotinic Agonists, Magnetic Resonance Imaging, Smoking Cessation, Varenicline, 11 Medical and Health Sciences, 17 Psychology and Cognitive Sciences, Psychiatry | ||||||||
SGUL Research Institute / Research Centre: | Academic Structure > Institute of Medical & Biomedical Education (IMBE) Academic Structure > Institute of Medical & Biomedical Education (IMBE) > Centre for Biomedical Education (INMEBE) |
||||||||
Journal or Publication Title: | Psychopharmacology (Berl) | ||||||||
ISSN: | 1432-2072 | ||||||||
Language: | eng | ||||||||
Dates: |
|
||||||||
Publisher License: | Creative Commons: Attribution 4.0 | ||||||||
PubMed ID: | 38430396 | ||||||||
Go to PubMed abstract | |||||||||
URI: | https://openaccess.sgul.ac.uk/id/eprint/116298 | ||||||||
Publisher's version: | https://doi.org/10.1007/s00213-024-06556-2 |
Statistics
Actions (login required)
Edit Item |